Vamorolone 0.25 mg/day/day

DRUG2 trials

Sponsors

ReveraGen BioPharma, Inc.

Conditions

Duchenne Muscular Dystrophy

Phase 2

An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

CompletedNCT02760277

ReveraGen BioPharma, Inc.Duchenne Muscular Dystrophy

Start: 2016-07-28End: 2018-04-26Updated: 2019-07-23

Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

CompletedNCT03038399

ReveraGen BioPharma, Inc.Duchenne Muscular Dystrophy

Start: 2017-02-02End: 2020-04-30Updated: 2021-05-20

Related Papers

Return of participant-level clinical trial results to participants: pilot of a simplified centralised approach

BMJ Open2024-03-011 citations

Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy

JAMA Network Open2022-01-2578 citations

Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study

PLoS Medicine2020-09-2177 citations